Julio Gonzalez-Paoli, MD
Rheumatology · Tampa, FLNPI 1336331271
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $991,351 of the $1,361,662 with a category attached, or 72.8%. It is spread thinly across 35 manufacturers, the largest accounting for just 20.9%. Among rheumatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,758 payments — averaging $493.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$285K
- GSK$276K
- Novartis$195K
- UCB, Inc.$189K
- AstraZeneca$130K
- Sanofi$83K
- plus $204K from 29 others
Across 272 payments — averaging $4499.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$595K
- Eli Lilly$279K
- Novartis$166K
- UCB SA$65K
- E.r. Squibb & Sons, L.L.C.$60K
- GSK$51K
- plus $8K from 2 others
What the payments were for
- Consulting fees$220,39316%
- Speaking & faculty fees$991,35173%
- Travel & lodging$88,6567%
- Food & beverage$60,7004%
- Education$5620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(3 entities) | 313 | $285,074 |
| GSK | 260 | $276,337 |
| Novartis | 337 | $195,102 |
| UCB, Inc. | 335 | $189,013 |
| AstraZeneca(2 entities) | 211 | $129,511 |
| Sanofi | 118 | $82,859 |
| Amgen(2 entities) | 420 | $51,799 |
| Janssen Scientific Affairs, LLC | 46 | $48,276 |
| AbbVie | 301 | $40,121 |
| Aurinia Pharma U.S., Inc. | 60 | $28,093 |
| E.r. Squibb & Sons, L.L.C. | 65 | $11,996 |
| Pfizer(2 entities) | 82 | $10,870 |
| Lilly USA, LLC | 46 | $3,419 |
| Regeneron Healthcare Solutions, Inc. | 10 | $3,237 |
| Gilead | 2 | $1,378 |
| UCB SA | 1 | $1,140 |
| Mallinckrodt Hospital Products Inc. | 45 | $990 |
| Genentech USA, Inc. | 19 | $352 |
| Sobi, Inc | 13 | $267 |
| ANI Pharmaceuticals, Inc. | 13 | $263 |
| Fresenius Kabi USA, LLC | 13 | $258 |
| Genentech, Inc. | 3 | $191 |
| Boehringer Ingelheim | 9 | $188 |
| Sanofi-aventis U.S. LLC | 3 | $174 |
| Bristol Myers Squibb | 3 | $172 |
| Kyowa Kirin, Inc. | 8 | $158 |
| Organon | 6 | $109 |
| Medtronic | 3 | $80 |
| IBSA Pharma Inc. | 3 | $55 |
| Radius Health, Inc. | 3 | $54 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Antares Pharma, Inc. | 1 | $16 |
| Sandoz | 1 | $14 |
| Medexus Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,361,662 in reported general payments places this provider in the 95th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 59 | $568,130 |
| Enbrel SureclickEtanercept | 66 | $520,111 |
| RinvoqUpadacitinib | 55 | $400,341 |
| TremfyaGuselkumab | 21 | $287,990 |
| BenlystaBelimumab | 34 | $143,799 |
| Taltz AutoinjectorIxekizumab | 16 | $122,011 |
| KevzaraSarilumab | 27 | $116,703 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $77,404 |
| OrenciaAbatacept/Maltose | 13 | $66,515 |
| ActemraTocilizumab | 22 | $52,205 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $30,142 |
| MethotrexateMethotrexate Sodium | 285 | $6,743 |
| Celecoxib | 213 | $6,453 |
| Leflunomide | 119 | $6,068 |
| Mycophenolate Mofetil | 61 | $5,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $40,121 | $400,34155 claims |
| Johnson & JohnsonTremfya | $285,074 | $287,99021 claims |
| GSKBenlysta | $276,337 | $143,79934 claims |
| SanofiKevzara | $82,859 | $116,70327 claims |
| UCB, Inc.Cimzia (2 Pack) | $189,013 | $77,40412 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $11,996 | $66,51513 claims |
| Genentech, Inc.Actemra | $191 | $52,20522 claims |
| AmgenEvenity (2 Syringes) | $51,799 | $30,14212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Tampa
- John CarterTampa$213K
- Yih Chang LinTampa$114K
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
- Ernesto RodriguezZephyrhills$958K
- Vinicius Costa Diniz DominguesDaytona Beach$921K
- Jonathan GreerBoynton Beach$757K
- Jigar ShahMargate$750K
- Rachel TateHollywood$729K
- Howard BuschLoxahatchee$717K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.